GlowTest COVID-19 Antigen Home Test Kit Usability Study

Sponsor
Arion Bio (Industry)
Overall Status
Completed
CT.gov ID
NCT05172154
Collaborator
CSSi Life Sciences (Industry)
35
1
15
71

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the usability of the GlowTest COVID-19 Antigen Home Test in Home Use.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: GlowTest COVID-19 Antigen Home Test Kit

Detailed Description

The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection. The test is intended for non-prescription home use with self collected direct anterior nares swab samples from individuals ages 14 years and older or adult collected anterior nares swab samples from individuals aged 2 to 13.

Study Design

Study Type:
Observational
Actual Enrollment :
35 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
GlowTest COVID-19 Antigen Home Test Kit Usability
Actual Study Start Date :
Dec 30, 2021
Actual Primary Completion Date :
Jan 12, 2022
Actual Study Completion Date :
Jan 14, 2022

Arms and Interventions

Arm Intervention/Treatment
15 subjects testing themselves

15 subjects 14 years of age and older

Diagnostic Test: GlowTest COVID-19 Antigen Home Test Kit
The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection

15 subjects testing someone else

15 adult subjects testing individuals ages 2-13

Diagnostic Test: GlowTest COVID-19 Antigen Home Test Kit
The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection

Outcome Measures

Primary Outcome Measures

  1. Assess the usability of the Quick Reference Instructions (QRI) based upon observer evaluation. [90 minutes]

    Track the percentage of subjects who perform the test correctly and according to the QRI.

  2. Assess the usability of the kit for home use based upon participant evaluation [90 minutes]

    Track usability of the test by asking subjects a series of questions regarding the ease of use of the test.

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. An Institutional Review Board (IRB) approved informed consent/assent is signed and dated prior to any study-related activities.

  2. Male and female Subjects 2 years of age and older.

  3. Subject is willing to provide a self-collected nasal swab sample. (If under the age of 14, the sample will be collected by an adult.)

  4. Subject agrees to complete all aspects of the study.

Exclusion Criteria:
  1. Subject has a visual impairment that cannot be restored with glasses or contact lenses.

  2. Subject has prior medical or laboratory training.

  3. Subject uses home diagnostics, e.g., glucose meters, HIV tests.

  4. Subject has prior experience with home COVID test kits

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centennial Medical Elkridge Maryland United States 21075

Sponsors and Collaborators

  • Arion Bio
  • CSSi Life Sciences

Investigators

  • Principal Investigator: Steven Geller, MD, Centennial Medical Group

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Arion Bio
ClinicalTrials.gov Identifier:
NCT05172154
Other Study ID Numbers:
  • AB-001-02
First Posted:
Dec 29, 2021
Last Update Posted:
Jan 19, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2022